MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 in ALS at 26th International Symposium on ALS/MND in Orlando, FL

MediciNova, Inc. MNOV announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, today presented interim data from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Orlando, FL.  The interim analysis includes a total of 36 subjects, and 33 of those subjects completed 6 months of treatment on study drug (MN-166 or placebo in a 2:1 ratio). Major highlights from the presentation, "Adaptive Design Single Center Phosphodiesterase Type 4 (PDE4) Inhibitor – Ibudilast (MN-166) Phase 1b/2a Clinical Trial [NCT02238626] for Amyotrophic Lateral Sclerosis (ALS) Patients [1] Not Requiring Non-Invasive Ventilation (no-NIV) up to 5 years and [2] Requiring Non-Invasive Ventilation (NIV) up to 10 years from Disease Onset," include the following: The rate of decline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score, a measure of functional impairment, from Baseline to Month 6 for the MN-166 and placebo subjects combined is below See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!